BioCentury
ARTICLE | Financial News

Cancer play Xynomic raises series B

June 7, 2018 11:10 PM UTC

Xynomic Pharmaceuticals Inc. (Dover, Del.) raised an undisclosed amount on June 1 in a series B round led by Northern Light Venture Capital, Zhongshan Bison Healthcare Investment and Hakim Unique Internet Co. All of the company's existing investors, including Prosperico Ventures and Xynomic Chairman Yinglin Mark Xu, also participated.

In the next year, Xynomic plans to start four pivotal trials of lead candidate abexinostat, a histone deacetylase (HDAC) inhibitor. The trials will evaluate abexinostat to treat metastatic renal cell carcinoma (RCC), relapsing-remitting follicular lymphoma and relapsing-remitting diffuse large B cell lymphoma (DLBCL). The follicular lymphoma and DLBCL studies will be conducted in China, while the others will be global studies, Xynomic said...